Improved overall survival in melanoma with combined dabrafenib and trametinib by Robert, Caroline et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Improved overall survival in melanoma with combined dabrafenib and
trametinib
Robert, Caroline; Karaszewska, Boguslawa; Schachter, Jacob; Rutkowski, Piotr; Mackiewicz, Andrzej;
Stroiakovski, Daniil; Lichinitser, Michael; Dummer, Reinhard; Grange, Florent; Mortier, Laurent;
Chiarion-Sileni, Vanna; Drucis, Kamil; Krajsova, Ivana; Hauschild, Axel; Lorigan, Paul; Wolter, Pascal;
Long, Georgina V; Flaherty, Keith; Nathan, Paul; Ribas, Antoni; Martin, Anne-Marie; Sun, Peng;
Crist, Wendy; Legos, Jeff; Rubin, Stephen D; Little, Shonda M; Schadendorf, Dirk
Abstract: BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as
monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K
mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone,
enhanced antitumor activity in this population of patients. METHODS In this open-label, phase 3 trial,
we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive
either a combination of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) or vemurafenib
(960 mg twice daily) orally as first-line therapy. The primary end point was overall survival. RESULTS
At the preplanned interim overall survival analysis, which was performed after 77% of the total number
of expected events occurred, the overall survival rate at 12 months was 72% (95% confidence interval
[CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group
(hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P=0.005). The
prespecified interim stopping boundary was crossed, and the study was stopped for efficacy in July 2014.
Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in
the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001). The objective response
rate was 64% in the combination-therapy group and 51% in the vemurafenib group (P<0.001). Rates
of severe adverse events and study-drug discontinuations were similar in the two groups. Cutaneous
squamous-cell carcinoma and keratoacanthoma occurred in 1% of patients in the combination-therapy
group and 18% of those in the vemurafenib group. CONCLUSIONS Dabrafenib plus trametinib, as
compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated
patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall
toxicity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01597908.).
DOI: 10.1056/NEJMoa1412690
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-107163
Published Version
Originally published at:
Robert, Caroline; Karaszewska, Boguslawa; Schachter, Jacob; Rutkowski, Piotr; Mackiewicz, Andrzej;
Stroiakovski, Daniil; Lichinitser, Michael; Dummer, Reinhard; Grange, Florent; Mortier, Laurent; Chiarion-
Sileni, Vanna; Drucis, Kamil; Krajsova, Ivana; Hauschild, Axel; Lorigan, Paul; Wolter, Pascal; Long,
Georgina V; Flaherty, Keith; Nathan, Paul; Ribas, Antoni; Martin, Anne-Marie; Sun, Peng; Crist,
Wendy; Legos, Jeff; Rubin, Stephen D; Little, Shonda M; Schadendorf, Dirk (2015). Improved overall
survival in melanoma with combined dabrafenib and trametinib. New England Journal of Medicine,
372(1):30-39. DOI: 10.1056/NEJMoa1412690
2
original article
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 372;1 nejm.org january 1, 201530
Improved Overall Survival in Melanoma  
with Combined Dabrafenib and Trametinib
Caroline Robert, M.D., Ph.D., Boguslawa Karaszewska, M.D., Jacob Schachter, M.D., 
Piotr Rutkowski, M.D., Ph.D., Andrzej Mackiewicz, M.D., Ph.D.,  
Daniil Stroiakovski, M.D., Michael Lichinitser, M.D., Reinhard Dummer, M.D., 
Florent Grange, M.D., Ph.D., Laurent Mortier, M.D., Vanna Chiarion-Sileni, M.D., 
Kamil Drucis, M.D., Ph.D., Ivana Krajsova, M.D., Axel Hauschild, M.D., Ph.D., 
Paul Lorigan, M.D., Pascal Wolter, M.D., Georgina V. Long, M.D., Ph.D.,  
Keith Flaherty, M.D., Paul Nathan, M.D., Ph.D., Antoni Ribas, M.D., Ph.D.,  
Anne-Marie Martin, Ph.D., Peng Sun, Ph.D., Wendy Crist, B.A., Jeff Legos, Ph.D., 
Stephen D. Rubin, M.D., Shonda M. Little, M.P.H., and Dirk Schadendorf, M.D.
The authors’ affiliations are listed in the 
Appendix. Address reprint requests to 
Dr. Robert at the Dermatology Service 
and INSERM Unité 981, Gustave Roussy, 
114 rue Edouard Vaillant, 94 805 Villejuif-
Paris Sud, France, or at caroline.robert@
gustaveroussy.fr.
This article was published on November 16, 
2014, at NEJM.org.
N Engl J Med 2015;372:30-9.
DOI: 10.1056/NEJMoa1412690
Copyright © 2014 Massachusetts Medical Society.
A BS TR AC T
Background
The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as mono-
therapies in patients with previously untreated metastatic melanoma with BRAF 
V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor tra-
metinib, as compared with dabrafenib alone, enhanced antitumor activity in this 
population of patients.
Methods
In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic 
melanoma with a BRAF V600 mutation to receive either a combination of dabrafenib 
(150 mg twice daily) and trametinib (2 mg once daily) or vemurafenib (960 mg twice 
daily) orally as first-line therapy. The primary end point was overall survival.
Results
At the preplanned interim overall survival analysis, which was performed after 77% 
of the total number of expected events occurred, the overall survival rate at 12 months 
was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group 
and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the 
combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P = 0.005). The prespecified 
interim stopping boundary was crossed, and the study was stopped for efficacy in 
July 2014. Median progression-free survival was 11.4 months in the combination-
therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% 
CI, 0.46 to 0.69; P<0.001). The objective response rate was 64% in the combination-
therapy group and 51% in the vemurafenib group (P<0.001). Rates of severe adverse 
events and study-drug discontinuations were similar in the two groups. Cutaneous 
squamous-cell carcinoma and keratoacanthoma occurred in 1% of patients in the 
combination-therapy group and 18% of those in the vemurafenib group.
Conclusions
Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, signifi-
cantly improved overall survival in previously untreated patients with metastatic 
melanoma with BRAF V600E or V600K mutations, without increased overall toxicity. 
(Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01597908.)
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The treatment of metastatic mela-noma is rapidly evolving. The potent and specific BRAF inhibitors vemurafenib and 
dabrafenib, as compared with chemotherapy, have 
significantly improved response rates, along with 
progression-free and overall survival, in patients 
with metastatic melanoma with BRAF V600E or 
V600K mutations.1,2 However, acquired resistance 
to BRAF inhibitors frequently develops through 
reactivation of the mitogen-activated protein ki-
nase (MAPK) pathway, resulting in a median pro-
gression-free survival of 6 to 8 months.2-5 In ad-
dition, the use of BRAF inhibitors may result in 
the development of secondary skin tumors, orig-
inating from a paradoxical activation of the MAPK 
pathway in cells without a BRAF mutation.1,6-11 
Combining a BRAF inhibitor with a MEK inhibi-
tor addresses the limitations of single-agent BRAF 
inhibitors and results in a significant delay in the 
emergence of resistance, with a longer median 
progression-free survival than with dabrafenib 
alone, as well as a decreased incidence of BRAF-
inhibitor–induced skin tumors.12-14
In this open-label, randomized, phase 3 study, 
we evaluated the effect of combination therapy 
with dabrafenib plus trametinib versus vemu-
rafenib monotherapy on overall survival in previ-
ously untreated patients with unresectable stage 
IIIC or IV melanoma with BRAF V600E or V600K 
mutations.
Me thods
Patients
From June 2012 through October 2013, a total of 
1645 patients were screened at 193 centers world-
wide. The presence of BRAF V600E or V600K muta-
tions was centrally determined with the investiga-
tional use of the THxID BRAF assay (bioMérieux). 
Additional key eligibility criteria were measureable 
disease, according to the Response Evaluation Cri-
teria in Solid Tumors (RECIST), version 1.1,15 and 
an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 or 1 (on a scale of 0 to 5, 
with 0 indicating no symptoms and higher num-
bers reflecting greater disability).16 Patients who 
had undergone treatment for brain metastases with 
no increase in lesion size for at least 12 weeks were 
eligible for enrollment. Additional eligibility cri-
teria are provided in the Methods section in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org. Written informed 
consent was obtained from all study participants.
Study Design and Treatment
Eligible patients were assigned in a 1:1 ratio to 
receive either a combination of dabrafenib (150 
mg orally twice daily) and trametinib (2 mg oral-
ly once daily) or vemurafenib (960 mg orally 
twice daily). The primary end point was overall 
survival. Secondary end points included progres-
sion-free survival, overall response rate, duration 
of response, and safety. Crossover was prohibited 
until the independent data and safety monitoring 
committee recommended stopping the study 
early for efficacy. After the recommendation, the 
study protocol was amended to allow patients in 
the vemurafenib group to cross over to the com-
bination-therapy group.
Assessment
We conducted tumor assessments according to 
RECIST, version 1.1,15 at baseline, every 8 weeks 
until week 56, and then every 12 weeks until dis-
ease progression, death, or withdrawal from the 
study (Table S1 in the Supplementary Appendix). 
All responses were confirmed with a scan at least 
4 weeks after the first RECIST response. Adverse 
events were graded by the investigator, according 
to the National Cancer Institute Common Termi-
nology Criteria for Adverse Events, version 4.0, 
until day 30 after the discontinuation of study 
treatment.
Study Oversight
The study was funded by the sponsor, Glaxo-
SmithKline, and conducted in accordance with 
the provisions of the Declaration of Helsinki and 
Good Clinical Practice guidelines. The protocol 
was approved by the institutional review board or 
human research ethics committee at each study 
center. Data were collected at each study site and 
monitored by the sponsor. The first author wrote 
the first draft of the manuscript, with support 
from the last author and representatives of the 
sponsor. Representatives of the sponsor designed 
the study, confirmed the accuracy of the data, 
and compiled the data for analysis. All the au-
thors and sponsor representatives had full access 
to the study data and were involved in their anal-
ysis. No one who was not an author contributed 
to the writing of the manuscript. Editorial assis-
tance that did not involve writing was provided 
by SciMentum and funded by the sponsor. All the 
authors vouch for the accuracy and completeness 
of the data reported and for the fidelity of the 
study to the protocol (available at NEJM.org).
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Statistical Analysis
We used the Kaplan–Meier method to estimate 
overall and progression-free survival. We evalu-
ated between-group comparisons using a log-
rank test that was stratified for the BRAF muta-
tion status (V600E vs. V600K) and the baseline 
level of lactate dehydrogenase (LDH) (above the 
upper limit of the normal range vs. the upper 
limit of the normal range or less). We estimated 
that 288 events would be required to detect a 
hazard ratio for death of 0.675 with an alpha 
level of 0.05 (i.e., an increase in median overall 
survival from 13.5 months in the vemurafenib 
group to 20 months in the combination-therapy 
group). Overall survival was defined as the time 
from randomization until death from any cause.
A preplanned interim analysis for overall sur-
vival was to be conducted when 202 of 288 
events that were required for the final analysis 
(70%) had been observed. Owing to the inherent 
lag in data entry, the actual number of deaths 
was 222 at the time of the interim analysis. Per 
protocol, efficacy boundaries were adjusted on 
the basis of the actual number of deaths at the 
time of the interim analysis. The data and safety 
monitoring committee used the adjusted stop-
ping boundaries (two-sided P<0.0214 for the ef-
ficacy analysis and P>0.2210 for the futility 
analysis) to review the interim data. The com-
mittee recommended stopping for efficacy. As 
such, the interim summary is considered to be 
the final analysis of overall survival.
R esult s
Patients
Of the 1645 patients who underwent screening at 
193 centers, 704 underwent randomization, with 
352 patients in each group. A total of 68 patients 
(10%, 34 in each study group) had a BRAF V600K 
mutation. Baseline characteristics of the patients 
are provided in Table 1. Known prognostic mea-
sures were well balanced in the two groups ex-
cept for sex (59% men in the combination-thera-
py group vs. 51% in the vemurafenib group). At 
the date of the analysis, the median follow-up 
durations were 11 months and 10 months and 
the median exposure durations were 10 months 
and 6 months in the combination-therapy group 
and the vemurafenib group, respectively.
A total of 80 patients in the combination-
therapy group and 81 in the vemurafenib group 
(23% in each group) continued to receive study 
treatment for at least 15 days after disease pro-
gression, according to the protocol, which al-
lowed for treatment after progression on the 
basis of a request from an investigator for pa-
tients who seemed to benefit from the treatment 
in spite of RECIST progression. The median 
duration of study treatment after progression 
was similar in the two study groups and was less 
than 3 months for the majority of patients, with 
more patients continuing to receive the combi-
nation therapy for 6 to 12 months (9%), as com-
pared with those who continued to receive ve-
murafenib (1%) (Table S2 in the Supplementary 
Appendix).
Efficacy
The interim analysis for overall survival was per-
formed in the intention-to-treat population of 
352 patients in each group. At the data-cutoff 
date of April 17, 2014, the interim analysis was 
performed after 222 events had occurred. For the 
overall survival analysis, 100 patients (28%) in 
the combination-therapy group and 122 (35%) in 
the vemurafenib group had died (hazard ratio for 
death in the combination-therapy group, 0.69; 
95% confidence interval [CI], 0.53 to 0.89; 
P = 0.005) (Fig. 1A). The prespecified stopping 
boundary (P<0.0214) was crossed, and the study 
was stopped for efficacy on July 14, 2014. A pro-
tocol amendment was issued to allow crossover 
to the combination-therapy group for patients 
assigned to the vemurafenib group, but no pa-
tient had crossed over as of the effective data-
freezing date of June 27, 2014.
The median overall survival was 17.2 months 
for patients in the vemurafenib group and had 
not been reached for patients in the combina-
tion-therapy group (Fig. 1A). The rate of overall 
survival at 12 months was 72% (95% CI, 67 to 
77) in the combination-therapy group and 65% 
(95% CI, 59 to 70) in the vemurafenib group. The 
hazard ratios for the variables of V600 mutation 
type, sex, age (<65 years vs. ≥65 years), baseline 
LDH level, and ECOG status have been calcu-
lated, although these subgroup analyses were 
not powered to show a significant between-group 
difference. They all favored the combination-thera-
py group except for the subgroup of patients with 
an ECOG score of 1 (hazard ratio, 1.03) (Fig. 1B).
Median progression-free survival was longer 
in the combination-therapy group than in the 
vemurafenib group (11.4 months vs. 7.3 months; 
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hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001) 
(Fig. 2A). The hazard ratio for progression-free 
survival favored combination therapy in all sub-
groups (Fig 2B).
The objective response rate was 64% (95% CI, 
59 to 69) in the combination-therapy group ver-
sus 51% (95% CI, 46 to 57) in the vemurafenib 
group (P<0.001) (Table 2); the median duration 
Table 1. Characteristics of the Patients at Baseline (Intention-to-Treat Population).*
Characteristic
Dabrafenib plus   
Trametinib  
(N = 352)
Vemurafenib 
(N = 352)
All Patients 
(N = 704)
Median age (range) — yr 55 (18–91) 54 (18–88) 55 (18–91)
Male sex — no. (%) 208 (59) 180 (51) 388 (55)
Previous immunotherapy — no. (%)† 61 (17) 93 (26) 154 (22)
ECOG score — no./total no. (%)
0 248/350 (71) 248/352 (70) 496/702 (71)
1 102/350 (29) 104/352 (30) 206/702 (29)
BRAF mutation — no./total no. (%)‡
V600E 312/346 (90) 317/351 (90) 629/697 (89)
V600K 34/346 (10) 34/351 (10) 68/697 (10)
Tumor stage at screening — no./total  
no. (%)
IVM1c 221/351 (63) 208/351 (59) 429/702 (61)
IIIc, IVM1a, or IVM1b 130/351 (37) 143/351 (41) 273/702 (39)
Metastasis stage at screening — no./total 
no. (%)
M0 14/351 (4) 26/351 (7) 40/702 (6)
M1a 55/351 (16) 50/351 (14) 105/702 (15)
M1b 61/351 (17) 67/351 (19) 128/702 (18)
M1c 221/351 (63) 208/351 (59) 429/702 (61)
Baseline LDH — no./total no. (%)
Above ULN 118/351 (34) 114/352 (32) 232/703 (33)
ULN or less 233/351 (66) 238/352 (68) 471/703 (67)
Visceral disease at baseline — no./total 
no. (%)§
Yes 278/351 (79) 271/352 (77) 549/703 (78)
No 73/351 (21) 81/352 (23) 154/703 (22)
Number of disease sites at baseline — no./
total no. (%)‖
Fewer than 3 177/351 (50) 201/352 (57) 378/703 (54)
3 or more 174/351 (50) 151/352 (43) 325/703 (46)
* Data are missing in several categories for one patient in each study group because data were either missing or incor-
rect at baseline. There were no significant differences between the groups at baseline except for sex (P = 0.03). ECOG 
denotes Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, and ULN upper limit of the normal range.
† Previous immunotherapy included interferon-alfa, interferon-gamma, interleukin-2, granulocyte–macrophage colony-stim-
ulating factor, gangliosides, imiquimod, ipilimumab, and investigational antineoplastic vaccine. Interferon and interleukin 
were classified as biologics in the clinical database. They were reclassified as immunotherapy in this ad hoc analysis.
‡ Six patients in the combination-therapy group and one in the vemurafenib group had both BRAF V600E and V600K mu-
tations and thus were excluded from either subgroup.
§ Visceral disease was defined as that affecting the soft internal organs, including the lungs, heart, and the organs of the 
digestive, excretory, reproductive, and circulatory systems but excluding lymph nodes.
‖The number of disease sites is the number of unique target and nontarget lesions, as defined by the Response Evalua-
tion Criteria in Solid Tumors and identified by the investigator, not the number of metastases.
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Figure 1. Overall Survival in the Intention-to-Treat Population and Prespecified Subgroups.
Panel A shows Kaplan–Meier estimates of overall survival in the intention-to-treat population among patients re-
ceiving combination therapy with dabrafenib plus trametinib versus those receiving vemurafenib monotherapy. The 
hazard ratio for death in the combination-therapy group was 0.69 (95% confidence interval, 0.53 to 0.89; P = 0.005). 
The tick marks indicate the dates on which data were censored. Panel B shows hazard ratios and 95% confidence 
intervals for overall survival in prespecified subgroups of patients, according to various baseline characteristics. 
ECOG denotes Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, and ULN upper limit of the nor-
mal range.
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Figure 2. Progression-free Survival in the Intention-to-Treat Population and Prespecified Subgroups.
Panel A shows Kaplan–Meier estimates of progression-free survival (as assessed by the site investigators) in the in-
tention-to-treat population among patients receiving combination therapy with dabrafenib plus trametinib versus 
those receiving vemurafenib monotherapy. The hazard ratio for progression or death in the combination-therapy 
group was 0.56 (95% confidence interval, 0.46 to 0.69; P<0.001). The tick marks indicate the dates on which data 
were censored. Panel B shows hazard ratios and 95% confidence intervals for progression-free survival in prespeci-
fied subgroups of patients, according to various baseline characteristics.
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of response was 13.8 months (95% CI, 11.0 to 
not reached) and 7.5 months (95% CI, 7.3 to 9.3), 
respectively. In the combination-therapy group, a 
complete response was reported in 47 patients 
(13%), as compared with 27 patients (8%) in the 
vemurafenib group. The response rate for the BRAF 
V600E subgroup was similar to that in the over-
all population in both study groups: 64% in the 
combination-therapy group and 52% in the vemu-
rafenib group; in the BRAF V600K subgroup, the 
response rates were 65% and 44%, respectively.
After the discontinuation of study treatment, 
subsequent anticancer therapy was administered 
to 20% of the patients in the combination-ther-
apy group and 43% of the patients in the vemu-
rafenib group. The most common therapy after 
disease progression in the two groups was ipili-
mumab, which was administered to 12% of the 
patients in the combination-therapy group and 
22% of the patients in the vemurafenib group. 
Post-trial therapies are listed in Table S3 in the 
Supplementary Appendix.
Adverse Events
The safety analysis included the 699 patients who 
received at least one dose of a study drug (Table 
3, and Table S4 in the Supplementary Appendix). 
Most patients had adverse events that were 
deemed by the investigator to be related to the 
study treatment: 91% in the combination-therapy 
group and 98% in the vemurafenib group. The 
rates of permanent treatment discontinuation 
because of adverse events were similar (13% and 
12%, respectively). The most common reasons 
for discontinuation were pyrexia and decreased 
ejection fraction (3% for each event) in the com-
bination-therapy group and arthralgia (2%) in 
the vemurafenib group. Adverse events leading to 
dose reduction were reported in 33% of patients 
in the combination-therapy group and 39% of 
those in the vemurafenib group; adverse events 
leading to dose interruption occurred in 55% and 
56%, respectively. Pyrexia was the most common 
reason for dose interruption (30%) and dose re-
duction (14%) in the combination-therapy group. 
Rash was the most common reason for dose in-
terruption (14%) and dose reduction (11%) in the 
vemurafenib group.
The most frequent adverse events in the 
combination-therapy group were pyrexia (53%), 
nausea (35%), diarrhea (32%), chills (31%), fa-
tigue (29%), headache (29%), and vomiting 
(29%). In the vemurafenib group, the most fre-
quent adverse events were arthralgia (51%), rash 
(43%), alopecia (39%), diarrhea (38%), nausea 
(36%), and fatigue (33%). Skin toxic effects were 
more frequent in the vemurafenib group than in 
the combination-therapy group, in particular 
rash (43% vs. 22%), photosensitivity reaction 
(22% vs. 4%), hand–foot syndrome (25% vs. 4%), 
skin papillomas (23% vs. 2%), squamous-cell 
carcinomas and keratoacanthomas (18% vs. 1%), 
and hyperkeratosis (25% vs. 4%). Pyrexia was 
more frequent in the combination-therapy group 
than in the vemurafenib group (53% vs. 21%).
Grade 3 or 4 adverse events occurred in 52% 
of the patients in the combination-therapy group 
and in 63% of those in the vemurafenib group. 
Three fatal events occurred in each group; all 
were deemed by the investigator to be unrelated 
to the study drug. A total of 3 patients in the 
combination-therapy group died (2 patients 
from cerebral hemorrhage and 1 from brain-
stem hemorrhage), as did 3 in the vemurafenib 
group (1 patient each from acute coronary syn-
drome, cerebral ischemia, and pleural infection). 
Rates of noncutaneous cancers were similar in 
the two groups: 3 patients (1%) in the combina-
tion-therapy group and 2 (1%) in the vemu-
rafenib group. A new primary melanoma was 
reported in 2 (1%) in the combination-therapy 
group and 7 (2%) in the vemurafenib group. An 
asymptomatic decrease in cardiac ejection frac-
tion of grade 2 or 3 was reported in 8% of pa-
tients in the combination-therapy group and no 
Table 2. Investigator-Assessed Best Response (Intention-to-Treat 
Population).*
Response
Dabrafenib 
plus Trametinib 
(N = 351)
Vemurafenib 
(N = 350)
Type of response — no. (%)
Complete 47 (13) 27 (8)
Partial 179 (51) 153 (44)
Stable disease 92 (26) 106 (30)
Progressive disease 22 (6) 38 (11)
Not evaluated 11 (3) 26 (7)
Objective response rate
No. of patients with response (%)† 226 (64) 180 (51)
95% CI 59.1–69.4 46.1–56.8
Duration of response (95% CI) — mo 13.8 (11.0–NR) 7.5 (7.3–9.3)
* Data are missing for one patient in the combination-therapy group and two 
patients in the vemurafenib group because these patients did not have mea-
surable disease at baseline. NR denotes not reached.
† Included in the objective response are complete and partial responses. 
P<0.001 for the between-group difference of 13% (95% CI, 6 to 20).
The New England Journal of Medicine 
Downloaded from nejm.org at HAUPTBIBLIOTHEK UNIV ZUERICH on January 27, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
Combined Dabr afenib and Tr ametinib in Melanoma
n engl j med 372;1 nejm.org january 1, 2015 37
patients in the vemurafenib group. Two grade 1 
chorioretinopathy events were reported in the 
combination-therapy group and one in the ve-
murafenib group. In the vemurafenib group, 
grade 2 retinal-vein occlusion that was reported 
in 1 patient was considered to be related to the 
study drug; no retinal-vein occlusion was re-
ported in the combination-therapy group.
Discussion
In our study, patients with previously untreated 
metastatic melanoma with BRAF mutations who 
received combination therapy with dabrafenib 
and trametinib, as compared with vemurafenib 
monotherapy, had a relative reduction of 31% in 
the risk of death. Together with the previously 
reported phase 2 and phase 3 trials of dabrafenib 
plus trametinib, as compared with dabrafenib 
monotherapy,12,13 these data provide clear evi-
dence for the benefit of this combination therapy 
over BRAF monotherapy in prolonging survival. 
Only modest activity has been observed with sin-
gle-agent trametinib, or trametinib added to 
dabrafenib, in patients whose tumors have pro-
gressed while they were receiving dabrafenib 
monotherapy.17-19 Thus, our study shows that 
first-line use of both BRAF and MEK inhibitors 
Table 3. Adverse Events.*
Event
Dabrafenib plus Trametinib
(N = 350)
Vemurafenib
(N = 349)
Any Grade† Grade 3 Any Grade† Grade 3
number of patients (percent)
Clinically significant adverse events occurring  
in ≥10% of patients
Any event 343 (98) 167 (48) 345 (99) 198 (57)
Pyrexia‡ 184 (53) 15 (4) 73 (21) 2 (1)
Nausea 121 (35) 1 (<1) 125 (36) 2 (1)
Diarrhea 112 (32) 4 (1) 131 (38) 1 (<1)
Chills 110 (31) 3 (1) 27 (8) 0
Vomiting 101 (29) 4 (1) 53 (15) 3 (1)
Arthralgia 84 (24) 3 (1) 178 (51) 15 (4)
Rash 76 (22) 4 (1) 149 (43) 30 (9)
Alopecia 20 (6) 0 137 (39) 1 (<1)
Hand– foot syndrome§ 14 (4) 0 87 (25) 1 (<1)
Hyperkeratosis 15 (4) 0 86 (25) 2 (1)
Skin papilloma 6 (2) 0 80 (23) 2 (1)
Photosensitivity reaction 13 (4) 0 78 (22) 1 (<1)
Adverse events of interest occurring in <10% 
of patients
Cutaneous squamous-cell carcinoma 
(including keratoacanthoma)
5 (1) 5 (1) 63 (18) 60 (17)
Decrease in ejection fraction 29 (8) 13 (4) 0 0
Chorioretinopathy 2 (1) 0 1 (<1) 0
Dermatitis acneiform 22 (6) 0 20 (6) 4 (1)
* Included in the safety analysis are 699 patients who received at least one dose of a study drug.
† Grade 4 events occurred in 3 patients (with headache, asthenia, and an elevated aspartate aminotransferase level) in 
the combination-therapy group and in 5 patients (with hypertension, constipation, an elevated alanine aminotransfer-
ase level, and squamous-cell carcinoma) in the vemurafenib group. Grade 5 events occurred in 3 patients (with cerebral 
hemorrhage in 2 patients and brain-stem hemorrhage in 1 patient) in the combination-therapy group and in 3 patients 
(with acute coronary syndrome, cerebral ischemia, and pleural infection) in the vemurafenib group.
‡ Pyrexia was defined as a body temperature of 38.5°C or more.
§ The hand– foot syndrome includes the terms palmar–plantar erythrodysesthesia, plantar–palmar hyperkeratosis, and 
palmoplantar keratoderma.
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resulted in higher response rates and longer du-
rations of response, as well as delayed emergence 
of tumor resistance, which led to a significant 
overall survival benefit.
To evaluate a potential influence of subse-
quent anticancer therapies on the patients’ sur-
vival, we analyzed the treatments that they re-
ceived after progression in each group. More 
patients in the vemurafenib group received sub-
sequent anticancer therapy than in the combina-
tion-therapy group (43% vs. 20%). The most 
common postprogression therapy in the two 
groups was ipilimumab, which is known to pro-
long survival in patients with metastatic mela-
noma.20,21 The fact that the median duration of 
exposure to vemurafenib was 4 months shorter 
than that for the combination therapy might 
partly explain why more patients in the vemu-
rafenib group received postprogression therapy 
at this point. However, with more patients in the 
vemurafenib group having received a therapy 
that is known to affect overall survival, there is 
no evidence that differences in postprogression 
therapy contributed to the survival benefit seen 
in the combination-therapy group.
Post hoc subgroup analyses showed that the 
overall survival benefit was found in all prog-
nostic subgroups except for patients with an 
ECOG score of 1. The hazard ratio for these 
patients was 1.03, which is surprising, since 
other known prognostic factors, such as M1c 
stage, high LDH, and more than three sites of 
metastases, have hazard ratios that suggest a 
benefit for the combination therapy, as com-
pared with vemurafenib. To understand the re-
sults in this subpopulation of patients, we 
looked at their subsequent therapies and con-
ducted statistical tests for interactions with 
other prognostic factors. This observation did 
not appear to be driven by any specific factor 
and remains unexplained. Although no defini-
tive conclusions can be drawn for this subgroup, 
a Cox model showed a hazard ratio for overall 
survival that was consistent with the results in 
the overall population, after accounting for the 
simultaneous effect of prognostic factors cor-
rected for stratification factors.
Progression-free survival was also signifi-
cantly prolonged among patients receiving the 
combination therapy, a finding that confirms 
the results of the COMBI-d phase 3 study, which 
evaluated progression-free survival in a similar 
population of patients who were treated with 
dabrafenib plus trametinib, as compared with 
dabrafenib alone.13,22 The results are also con-
sistent with those of another study comparing 
vemurafenib plus cobimetinib with vemurafenib 
alone, which showed significant differences in 
progression-free survival of 9.9 and 6.2 months, 
respectively.14
The objective rate of tumor response was sig-
nificantly higher in the combination-therapy group 
than in the vemurafenib group (64% vs. 51%, 
P<0.001), as was the duration of response, with 
a median duration of response in the combina-
tion-therapy group that was almost twice as long 
as that in the vemurafenib group (13.8 months 
vs. 7.5 months). Notably, the rate of complete re-
sponse was also significantly higher in the combi-
nation-therapy group than in the vemurafenib 
group (13% vs. 8%, P = 0.02) in a post hoc analysis.
The overall safety profile in the combination-
therapy group shows that this regimen has fre-
quent low-grade toxicity. The incidences of grade 
3 or 4 toxic effects and of adverse effects leading 
to dose reduction or treatment interruption were 
similar in the two study groups, with no deaths 
that were deemed to be related to the study drug. 
The spectrum of adverse effects differed in the 
two groups, with the most common cause for 
treatment modification reported as pyrexia in the 
combination-therapy group and rash in the ve-
murafenib group. Pyrexia is usually easily man-
ageable with symptomatic treatment or transient 
interruption of dabrafenib or both dabrafenib 
and trametinib, with treatment reinitiation after 
the patient has been afebrile for a minimum of 
24 hours. The education of both patients and 
physicians regarding pyrexia management is 
paramount to ensure that this side effect is not 
prolonged or complicated. A decreased ejection 
fraction was more frequent with the combina-
tion therapy than with vemurafenib (8% vs. 0%), 
and this side effect has been observed previ-
ously with single-agent MEK inhibitors.14,17
Skin adverse effects were less frequent in the 
combination-therapy group, especially the events 
that are linked to a paradoxical activation of the 
MAPK pathway, including both benign and ma-
lignant skin tumors. This finding is in accor-
dance with preclinical models showing that the 
addition of MEK inhibitors may down-regulate 
the BRAF-inhibitor–induced paradoxical activa-
tion of the MAPK pathway.23-27 Thus, secondary 
resistance and paradoxical activation of the 
MAPK pathway that occur with BRAF-inhibitor 
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monotherapy, which translate into rapid tumor 
relapses and emergence of skin cancers, respec-
tively, were both improved by the combination 
therapy.
In conclusion, the combination of dabrafenib 
plus trametinib was superior to vemurafenib 
monotherapy with regard to all efficacy end 
points, including overall survival, with no addi-
tional overall toxicity.
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